Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Cyp2d6*10 polymorphisms on tamoxifen metabolism in breast cancer patients

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: PAO, Li-Heng (Chang Gung University of Science and Technology, Research Center for Industry of Human Ecology, Taoyuan, China Taiwan)
  • Co-author(s): Ho, Ya-Ting (School of Pharmacy, National Defense Medical Center, Taipei, China Taiwan)
    Lo, Chia-Yi (Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, China Taiwan)
    Dai, Ming-Shen (Department of Hematology and Oncology, Tri-Service General Hospital, Taipei, China Taiwan)
    Shih, Jui-Hu (Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, China Taiwan)
  • Abstract:

    Background: Tamoxifen has been the gold standard for reducing the risk of recurrence and mortality in adjuvant endocrine therapy. The active metabolites of tamoxifen, 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen), have been considered to have 100-fold greater affinity for estrogen receptors than the parent drug. Several study..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses